Abstract：Objective: To investigate the expression of lymphocyte function-associated antigen-1 (LFA-1) in chronic obstructive pulmonary disease (COPD) neutrophilic inflammation and its clinical significance. Methods: A total of 40 patients with acute exacerbation of COPD (AECOPD) who were in the Huizhou Central People's Hospital from January 2019 to December 2020 were made the AECOPD group, another 40 patients with stable COPD were made the stable COPD group, and 20 healthy volunteers served as a control group. Comparison was conducted among groups on LFA-1 with neutrophilic factors [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), inflammatory Protein thymic stromal lymphopoietin (TSLP), high mobility group protein 1 (HMGB1)] and their correlations, and different clinical characteristics of LFA-1 levels and their independent influencing factors were analyzed. Results: Comparison of the levels of LFA-1, TNF-α, IL-6, IL-8, TSLP and HMGB1 in the three groups: AECOPD group>COPD stable>control group, all were statistically significant (P<0.05). According to Pearson analysis, LFA-1 is not correlated with TNF-α, TSLP, HMGB1 (P>0.05), and LFA-1 is positively correlated with IL-6, IL-8 (P<0.05). According to univariate analysis, smoking, chronic obstructive pulmonary disease assessment test (CAT) score, modified version of British Medical Research Council respiratory questionnaire (mMRC) classification, Global Initiative for Chronic Obstructive Lung Diseas (GOLD) classification are the factors that affect LFA-1 levels (P<0.05); After multiple linear regression analysis, smoking, CAT score, mMRC classification, and GOLD are independent risk factors that affect LFA-1 levels(P<0.05). Conclusion: COPD patients have high expression of LFA-1 and neutrophilic factors, and AECOPD is higher than that of patients with stable COPD. COPD patients LFA-1 and LFA-1 are related to neutrophilic factors. Smoking, CAT score ≥10, mMRC grade ≥ 2, GOLD grade ≥2 are the reasons for the high level of LFA-1.
林宇挺, 李伟坚, 黄培楷. LFA-1在慢性阻塞性肺疾病中性粒细胞性炎症反应的作用探讨[J]. 河北医学, 2021, 27(12): 1974-1978.
LIN Yuting, LI Weijian, HUANG Peikai. The Role of LFA-1 in the Neutrophilic Inflammatory Response of Chronic Obstructive Pulmonary Disease. HeBei Med, 2021, 27(12): 1974-1978.
[1] Negi H,Sarkar M,Raval AD,et al.Presence of depression & its risk factors in patients with chronic obstructive pulmonary disease[J].Indian Med Res,2019,139(3):402~408. [2] 施海祯,刘海玲,王淦楠,等.中性粒细胞/淋巴细胞比率和凝血功能异常对慢性阻塞性肺疾病严重程度的判断价值[J].临床急诊杂志,2019,20(6):445~449. [3] 梁群娣,吴文军,佘子瑜.颈动脉粥样硬化斑块患者淋巴细胞功能相关抗原-1,可溶性CD40,组织蛋白酶K水平分析[J].心脑血管病防治,2021,21(1):93~94,98. [4] Liao YX,Chen YH.Twenty years of changes in the disease assessment method of the global initiative for chronic obstructive lung disease[J].Chin Med,2020,133(17):2098~2103. [5] Sengupta S,Dey D,Bhattacharyya P.Correlating between chronic obstructive pulmonary disease assessment test and emPHasis score in Group III pulmonary hypertension patients.[J].Lung India,2019,36(1):86~87. [6] Ciftci F,Sen E,Akkoca Yildiz o,et al.Does exercise capacity,dyspnea level,or quality of life actually predict mortality in patients with COPD 8-year follow-up.[J].Tuberk Toraks,2019,67(2):83~91. [7] Wedzicha JA,Miravitlles M,Hurst JR,et al.Management of COPD exacerbations:a european respiratory society/American thoracic society guideline[J].Eur Respir,2017,49(3):1600791. [8] Hoogendoorn M,Corro Ramos I,Baldwin M,et al.Broadening the perspective of cost-effectiveness modeling in chronic obstructive pulmonary disease:a new patient-level simulation model suitable to evaluate stratified medicine[J].Value Healthm,2019,22(3):313~321. [9] 赵娅,张松,李媛媛,等.有氧运动对高血脂大鼠疾病模型血脂及ICAM-1和LFA-1的影响[J].中国医师杂志,2019,21(4):49~52,59. [10] 任波,李瑞丽,袁晓锋.两种药物治疗小儿急性呼吸道感染对患儿血清CRP PA和IL-6水平的影响比较[J].河北医学,2021,27(2):339~343. [11] 朱建光,沈露,张潮,等.儿童哮喘患者血清IL-33和TSLP水平检测的临床意义及与IgE相关性分析[J].现代检验医学杂志,2019,34(1):64~67. [12] 陈玥琪,苏兆亮,夏琳.高迁移率族蛋白B1在肿瘤中的双重作用[J].中华微生物学和免疫学杂志,2021,41(3):221~225. [13] 韩曙光,刘玲,冯金萍,等.血清HMGB1、IL-27水平及CAT评分与COPD合并Ⅱ型呼吸衰竭的关系分析[J].国际呼吸杂志,2019,39(17):1297~1301.
2021, Vol. 27 
冀公网安备13080202000677号